This vaccine candidate, code-named mRNA-1273, was developed by the NIH and Massachusetts-based biotechnology company Moderna Inc. There's no chance participants could get infected from the shots because they don't contain the coronavirus itself. | Above: Pharmacist Michael Witte, left, gives Rebecca Sirull, right, a shot in the first-stage safety study clinical trial. Sirull is the third patient to receive the shot in the study.
AP